| | The Right LIMS for COVID-19 Research LabVantage COVID-19 LIMS keeps pace with increasing COVID-19 sample volumes and research studies. Learn how one research center uses extraction and testing workflows, CDC test methods, and more to fight the coronavirus pandemic. Download our report. |
Russian hackers feverishly working to steal COVID-19 vaccine research, governments say Fauci calls for U.S. to hit 'reset button' after some states reopened too quickly Johnson & Johnson to start human testing of COVID-19 vaccine next week CVS, Walmart lead retailers adding requirements for face masks in all stores Novartis promises zero profit for 15 symptomatic COVID-19 drugs in low-income countries COVID-19 close-up: Nocion CEO Batycky on controlling cough to control spread Here's a look at what docs' average starting salaries were—before COVID-19 hit Biopharma roundup: HHS upholds Slaoui's contractor status; China offers unapproved Sinopharm shots to state employees Thermo Fisher throws in an extra billion to buy COVID-19 testing supplier Qiagen Adagio debuts with $50M to fight COVID-19—and the next pandemic House telehealth leaders move to cement regulatory changes for virtual care While the pandemic is still spiking, clinical trial disruptions starting to ease for now: analyst Report: Revenue for staffing firms up as demand soars for staff to help fight COVID-19 Featured Story | By Eric Sagonowsky COVID-19 vaccine researchers worldwide are working around the clock to advance promising candidates, but Russian hackers are simultaneously trying to swipe everything they've learned, officials from the U.S., U.K. and Canada said Thursday. read more |
| |
|---|
|
Top Stories By Tina Reed What will it take to get the U.S. back on track? Here's what the nation's top infectious disease expert thinks needs to happen next. read more By Eric Sagonowsky Several biopharma players are racing to deliver COVID-19 vaccines, and now Johnson & Johnson is revving up its plans for late-stage trials earlier than originally expected—and it's aiming far above the FDA's 50% efficacy bar for approval, executives said. If its candidate succeeds in the clinic, J&J plans to be ready to launch in early 2021. read more By Paige Minemyer As cases of the novel coronavirus spike in several states, two of the country's largest retailers will require customers to wear masks in all locations. read more By Angus Liu Novartis’ generic hydroxychloroquine may have little use in COVID-19, but the Swiss pharma still wants to contribute its low-cost drugs in some way. Its Sandoz unit will offer 15 generic and over-the-counter medicines, including dexamethasone, at zero profit to developing countries during the pandemic. read more By Amirah Al Idrus Suppressing cough in COVID-19 patients not only addresses a symptom that can be “traumatic and debilitating,” but it can tamp down on the spread of the disease from patients to hospital staff, family or housemates. Nocion Therapeutics scored expedited approval for the phase 1 study of its cough treatment. read more By Tina Reed Invasive cardiologists often receive the highest starting salaries at about $640,000 compared to other physician specialties, according to a review by national healthcare recruiting firm Merritt Hawkins. While that figure may not, of course, reflect current reality in the wake of the pandemic, here's a look at what docs were being offered. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner The HHS upheld Moncef Slaoui's position as a government contractor, shielding the Warp Speed chief from federal disclosure rules. Moderna execs have sold off far more shares in 2020 than other pharmas in the COVID-19 fight. And China is dosing employees of certain state-owned firms with Sinopharm's vaccine candidates—outside of official trials. read more By Conor Hale Thermo Fisher Scientific has sweetened its deal for diagnostic manufacturer Qiagen by about 10% after the spreading COVID-19 pandemic has heightened the value of molecular testing supplies. read more By Amirah Al Idrus Coronaviruses have jumped from animals to humans before—and they’ll do it again. That’s why Adagio Therapeutics is working on antibodies that can fight multiple members of the virus family, including SARS-CoV-2, the culprit behind the current pandemic. The startup snagged $50 million to push its lead candidates into the clinic. read more By Heather Landi Leaders of the House telehealth caucus introduced legislation Thursday to permanently open up access to telehealth services for Medicare patients. Here are the changes that the legislators are proposing. read more By Ben Adams It was a tough three months for clinical trials as they were hit by lockdowns, but, as many CROs predicted, things are starting to ease up. read more By Robert King Health staffing firms are finding an increase in revenue as demand for nursing staff to help treat COVID-19 patients reaches a fast pace read more |
